Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Here's Why Amedisys (AMED) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should You Buy HCA Healthcare (HCA) Ahead of Q1 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results are likely to reflect increased admissions and patient days.
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Quest Diagnostics (DGX) delivered earnings and revenue surprises of 9.68% and 3.30%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Amedisys (AMED) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Is Amedisys (AMED) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How Amedisys (AMED) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Amedisys (AMED) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Amedisys' (AMED) Q4 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q4 performance.
AMED vs. USPH: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMED vs. USPH: Which Stock Is the Better Value Option?
Amedisys (AMED) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Amedisys (AMED) Q4 Earnings Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -9.62% and 1.05%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings
by Zacks Equity Research
Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.
Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.
Centene (CNC) to Provide Better Health Equity in North Carolina
by Zacks Equity Research
Centene (CNC) collaborates with Reinvestment Partners to improve the health of North Carolinians.
Amedisys (AMED) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Philips (PHG) Q4 Earnings Beat Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Philips' (PHG) fourth-quarter results benefit from strong momentum across the Diagnosis & Treatment and Personal Health businesses. However, softness in the Connected Care business is a concern.
Chemed (CHE) Up 4.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Up 2.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys' (AMED) Q3 Earnings Miss Estimates, Margins Up
by Zacks Equity Research
The continuous shortage of clinical labor, nursing in particular, is likely to have impacted Amedisys' (AMED) Q3 performance.
Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Amedisys (AMED) delivered earnings and revenue surprises of -9.26% and 0.99%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein (HSIC) Acquires Majority Stake in Shield Healthcare
by Zacks Equity Research
Henry Schein (HSIC) completes the majority investment in Shield Healthcare, Inc.
Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.
Philips (PHG) Aids Clinicians With New Monitoring Solution
by Zacks Equity Research
Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.